Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate Lyon, France – December 5, 2019 – Osivax announced today that it has entered into an agreement with the United States’ National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to further advance the development …
Archives de la catégorie : 2019
Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate
Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate— Linda Lebon joins as Chief Regulatory Officer —— Florian Sourd joins as VP Finance — Lyon, France – October 30th, 2019 – Osivax announced today the appointment of Linda Lebon as Chief Regulatory Officer and Florian Sourd as VP …
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate– Full safety and immunogenicity results expected for end 2019 — Lyon, France – September 26th, 2019 – Osivax announced today that all participants have completed their final visit in the first-in-human clinical trial of OVX836 universal Influenza vaccine …
Osivax secures EUR 8 Million of Financing through a Series A Round
Osivax Secures EUR 8 Million of Financing through a Series A Round to Develop Novel Universal Flu Vaccines and Expand oligoDOM® Technology Platform — Company to establish new subsidiary office in Liege, Belgium — Lyon, France – July 10, 2019 – Osivax announced today that it has secured EUR 8 million of financing through a Series …
Continuer la lecture « Osivax secures EUR 8 Million of Financing through a Series A Round »
Osivax appoints Dr. Paul Willems as Chief Medical Officer
Paul Willems’ appointment will strengthen Osivax’s capacities to design and implement an ambitious and impactful clinical development plan for its vaccines pipeline and especially the “universal” flu vaccine program Lyon, France – January 31st, 2019 – Osivax, a clinical stage biopharmaceutical company currently focused on the development of a breakthrough “universal” influenza vaccine program, announced today …
Continuer la lecture « Osivax appoints Dr. Paul Willems as Chief Medical Officer »